The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sun, R.
Right arrow Articles by Wang, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sun, R.
Right arrow Articles by Wang, J. M.
The Journal of Immunology, 2004, 173: 428-436.
Copyright © 2004 by The American Association of Immunologists

Identification of Neutrophil Granule Protein Cathepsin G as a Novel Chemotactic Agonist for the G Protein-Coupled Formyl Peptide Receptor 1,2

Ronghua Sun*, Pablo Iribarren*, Ning Zhang*, Ye Zhou*, Wanghua Gong{dagger}, Edward H. Cho{ddagger}, Stephen Lockett{ddagger}, Oleg Chertov{dagger}, Filip Bednar§, Thomas J. Rogers§, Joost J. Oppenheim* and Ji Ming Wang3,*

* Laboratory of Molecular Immunoregulation, Center for Cancer Research, and {dagger} Basic Research Program and {ddagger} Image Analysis Laboratory, Science Applications International Corp.-Frederick, National Cancer Institute at Frederick, Frederick, MD 21702; and § Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140

The antimicrobial and proinflammatory neutrophil granule protein cathepsin G (CaG) has been reported as a chemoattractant for human phagocytic leukocytes by using a putative G protein coupled receptor. In an effort to identify potential CaG receptor(s), we found that CaG-induced phagocyte migration was specifically attenuated by the bacterial chemotactic peptide fMLP, suggesting these two chemoattractants might share a receptor. In fact, CaG chemoattracts rat basophilic leukemia cells (RBL cells) expressing the high affinity human fMLP receptor FPR, but not parental RBL cells or cells transfected with other chemoattractant receptors. In addition, a specific FPR Ab and a defined FPR antagonist, cyclosporin H, abolished the chemotactic response of phagocytes and FPR-transfected cells to CaG. Furthermore, CaG down-regulated the cell surface expression of FPR in association with receptor internalization. Unlike fMLP, CaG did not induce potent Ca2+ flux and was a relatively weaker activator of MAPKs through FPR. Yet CaG activated an atypical protein kinase C isozyme, protein kinase C{zeta}, which was essential for FPR to mediate the chemotactic activity of CaG. Thus, our studies identify CaG as a novel, host-derived chemotactic agonist for FPR and expand the functional scope of this receptor in inflammatory and immune responses.




This article has been cited by other articles:


Home page
Pharmacol. Rev.Home page
R. D. Ye, F. Boulay, J. M. Wang, C. Dahlgren, C. Gerard, M. Parmentier, C. N. Serhan, and P. M. Murphy
International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family
Pharmacol. Rev., June 1, 2009; 61(2): 119 - 161.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
O. Soehnlein and L. Lindbom
Neutrophil-derived azurocidin alarms the immune system
J. Leukoc. Biol., March 1, 2009; 85(3): 344 - 351.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. Huang, K. Chen, J. Huang, W. Gong, N. M. Dunlop, O.M.Z. Howard, X. Bian, Y. Gao, and J. M. Wang
Regulation of the leucocyte chemoattractant receptor FPR in glioblastoma cells by cell differentiation
Carcinogenesis, February 1, 2009; 30(2): 348 - 355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
O. Soehnlein, A. Zernecke, E. E. Eriksson, A. G. Rothfuchs, C. T. Pham, H. Herwald, K. Bidzhekov, M. E. Rottenberg, C. Weber, and L. Lindbom
Neutrophil secretion products pave the way for inflammatory monocytes
Blood, August 15, 2008; 112(4): 1461 - 1471.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Huang, J. Hu, X. Bian, K. Chen, W. Gong, N. M. Dunlop, O.M. Z. Howard, and J. M. Wang
Transactivation of the Epidermal Growth Factor Receptor by Formylpeptide Receptor Exacerbates the Malignant Behavior of Human Glioblastoma Cells
Cancer Res., June 15, 2007; 67(12): 5906 - 5913.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J.-L. Gao, A. Guillabert, J. Hu, Y. Le, E. Urizar, E. Seligman, K. J. Fang, X. Yuan, V. Imbault, D. Communi, et al.
F2L, a Peptide Derived from Heme-Binding Protein, Chemoattracts Mouse Neutrophils by Specifically Activating Fpr2, the Low-Affinity N-Formylpeptide Receptor
J. Immunol., February 1, 2007; 178(3): 1450 - 1456.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Stefanidakis and E. Koivunen
Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression
Blood, September 1, 2006; 108(5): 1441 - 1450.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
Y. Zhou, X. Bian, Y. Le, W. Gong, J. Hu, X. Zhang, L. Wang, P. Iribarren, R. Salcedo, O. M. Z. Howard, et al.
Formylpeptide Receptor FPR and the Rapid Growth of Malignant Human Gliomas
J Natl Cancer Inst, June 1, 2005; 97(11): 823 - 835.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
I. Migeotte, E. Riboldi, J.-D. Franssen, F. Gregoire, C. Loison, V. Wittamer, M. Detheux, P. Robberecht, S. Costagliola, G. Vassart, et al.
Identification and characterization of an endogenous chemotactic ligand specific for FPRL2
J. Exp. Med., January 3, 2005; 201(1): 83 - 93.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.